|
|
 |
 Home > About Hanmi > CompanyProfile > Hanmi at a glance |
|
 |
 |
| Leading Korean Pharmaceutical Company for the 21st Century! |
Hanmi Pharm. has been the leader in Korean pharmaceutical industry with creative and Passionate pursuit of new technologies led Hanmi become number one in drug prescription and number two in the total revenue in Korean pharmaceutical market. Hanmi¡¯s goal is to become a global pharmaceutical company competing with other multi-national pharmaceutical companies.
Global exporting was about USD 47 Million in 2005, and in 2006 exporting exceeded USD 55 Million. In 2007, with completion of new cephalosporin finished product manufacturing facility in Pyong-Taek, Hanmi is successfully knocking doors in Japan, Europe, and North America.
Hanmi Pharm. has become the benchmark of pharmaceutical company in Korea through determined and vigorous investment in R & D which led to creation of several successful incrementally modified products such as Amodipin while majority of other companies were concentrating on licensing of products from Original developers. Amodipin is incrementally modified product of Pfizer¡¯s blockbuster Norvasc. Its introduction to the market near the patent expiration of Norvasc was enormous success, currently occupying more than 30% of total Amlodipine market. |
| Another Sensation - New Product Development Project |
Hanmi¡¯s R & D strategy is divided in two segments. For long-term goal, Hanmi¡¯s concentrating on development of New Chemical or Molecular Entity. As a mid or short-term success, Hanmi has been developing IMDs and first-generics. These two segments are being pursued concurrently; however, Hanmi¡¯s ultimate strategy is to develop its own new products targeting the global market. Hanmi¡¯s new products in its developmental pipeline have been the focus of Korean public and Korea media. Hanmi¡¯s Long Acting Protein/Peptide Technology (LAPSCOVERY) and Oral Oncology Product Technology (ORASCOVERY) are the core of Hanmi¡¯s proprietary new drug product development platform technologies.
It has been demonstrated that LAPSCOVERY can be applied to variety of different biological products such as proteins, peptides, immuno-globulins (antibodies), enzymes, hormones, etc. to extend the half-life and currently, *Long-Acting EPO (HM 10760A), *Long-Acting G-CSF (HM10460A), *Long-Acting Exendin-4 analog (HM11260C), and 3 other long-acting products are in or near pre-clinical developmental stage.
The total markets for the these six long-acting proteins in the world exceed more than 21 Billion, in particular, HM11260D which is used in treatment of diabetes is expected to open door for Hanmi to enter one of the largest and richest market.
ORASCOVERY has potential to revolutionize the cancer treatment with offering oral dosage chemo-therapy treatment of currently available injection therapies. Since 2000, Hanmi¡¯s researchers have worked vigorously to develop Pgp inhibitor (oral absorption enhancer) candidate, HM-30181A.
With its success in IMDs and first generic strategy, Hanmi is now transforming to become New Chemical and Molecular Entity developer with investment in R & D. Hanmi plans to continue its resolute investment in R & D by channeling more than 10% of its total revenue to its research projects. Hanmi is determined to become leading global pharmaceutical company with core of bio-pharmaceutical products in its rich developmental pipeline. |
| Targeting the Boundless Global Market, Our Technologies and Our Products |
In 2005, Hanmi had an 11% increase in its export business from 2004 to finish the year with over USD 46 Million. In 2006, Hanmi¡¯s exporting figure exceeded USD 50 Million which allowed Hanmi to receive prestigious governmental recognition for first pharmaceutical company to export more than USD 50 Million in pharmaceutical products.
Currently, Hanmi¡¯s exporting business is mainly composed of cephalosporin API export which accounts for approximately 85% of the total export. Ceftriaxone, Ceftazidime, Cefotaxime, Cefixime, and Cefotiam are core of the API exports, and the quality has been recognized throughout the world. We expect continued growth in API exporting business in the future. Hanmi subsidiary company, Hanmi Fine Chemical, which manufactures API for pharmaceutical products, has been exporting pharmaceutical API to more than 30 countries in Europe, Middle East, Japan, South America, and China. Beijing Hanmi has been recognized as success story for pharmaceutical company for entering Chinese market. Since opening its door in 1996, Beijing Hanmi has shown substantial growth each year.
The ultimate goal of Hanmi is to become global pharmaceutical company competing against current multi-national companies. Hanmi will continue to vigorously search for new products and improve current products, endlessly conducting innovation in its technologies to pursue its ultimate goal. |
| |
|
|
|
